German trying to use PT to lower Lp(a) without success

[Frodo]

[Frodo]

[Frodo]

[Frodo]

Interesting
New video lecture by Dr. Matthias Rath: Ending the current pandemic (The optimal supply of micronutrients not only for corona)
https://www.dr-rath-foundation.org/2020 ... pandemics/

[Frodo]

[Frodo]

eDoc
I have a question. Not about Lp(a). But about pain after running. Are there successes in the treatment of sciatic- and hip pain with dmso? How much should I try?

[Frodo]

Remdesivir against Corona?
Dr. Matthias Rath wrote about it: https://www.dr-rath-foundation.org/2020 ... -pandemic/

[Frodo]

[Frodo]

[Frodo]

[Frodo]

pamojja

I found your post number 231 and your list of lp(a) values. Do you have the values of 2019 and 2020? Did they change? How much vitamin C, lysine and proline do you take?

[pamojja]

2019 it was 61 mg/dl. 2010 60. No changes of labs recently.

About 24g vitamin C, 6g lysine and 2g proline in average.

Code: Select all

year Lp(a) mg_Kyolic

2009   57    200
2010   47    690
2011   59    870
2012   55    830
2013   43    790
2014   47    420
2015   35    180
2016   51    620
2017   45    820
2018   58   1140

[Frodo]

[pamojja]

This does not correspond to the Pauling/Rath therapy.

I'm 53 and it does correspont to the Linus Pauling therapy. Rath's therapy is very different and uses only tiny doses in comparison.

https://patents.google.com/patent/US5278189A/en

SUMMARY OF THE INVENTION

The foregoing needs in the treatment and prevention of cardiovascular disease are met by the methods and compositions of the present invention.

A method is provided for the treatment of occlusive cardiovascular disease, comprising the step of administering to a subject an effective amount of ascorbate and one or more binding inhibitors, as a mixture or as a compound comprising ascorbate covalently linked with binding inhibitors, which inhibit the binding of Lp(a) to blood vessel walls, such as arterial walls. This effect may also be obtained by administering an effective amount of one or more inhibitors, without ascorbate. The term binding inhibitor throughout the specification and claims is intended to include all substances that have an affinity for the lysine binding site present on the interior walls of blood vessels, particularly arteries, the site of Lp(a) binding. Most of these substances compete with plasmin for the lysine binding site and some of these compounds, in high doses, are in clinical use for the treatment of hyperfibrinolytic states.

Even if it doesn't lower Lp(a), it still inhibits the binding of Lp(a) to blood vessel walls. Theoretically.

Practically I experienced a remission from a 60% walking-disablity due to PAD, a 80% stenosis at my abdominal aorta bifurcation. As unexpected side-effects further remissions: COPD, T2D, NAFLD, CKD, ME/CFS..

[Frodo]